As the Alibaba IPO nears, Cramer expects a slew of stocks to selloff. He's naming names.» Read More
Aug 13- Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its Incivek hepatitis C treatment, whose use has been largely supplanted by the new Sovaldi drug from Gilead Sciences Inc.. Incivek was approved in 2011 and quickly rose to annual sales of more than $1 billion.
It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Cramer likes to review the S&P 500’s Daily Action Charts in an effort to find stocks that could work higher.
Aug 1- Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both sold by Amgen Inc..
July 30- U.S. health insurer Humana Inc reported a lower profit owing to higher costs on Wednesday, as mounting concerns about increased medical spending drove health insurance industry shares lower for a second straight day.
July 30- U.S. health insurer Humana Inc said on Wednesday that second-quarter profit fell due to investments in the exchanges created under President Barack Obama's healthcare reform law as well as costly new hepatitis C drug treatments. Humana said membership growth and a lower share count due to stock buybacks had helped offset some of the new costs.
July 29- Aetna Inc, the third-largest U.S. health insurer, reported a rise in medical costs on Tuesday, raising investor concerns that a long run of low growth in such costs might be ending and pushing shares in the industry lower.
A new hepatitis drug could be significant for Arrowhead Research, CEO Chris Anzalone says.
NEW YORK, July 29- With some of Wall Street's more volatile names set to report in the next couple of days, traders who bet on big swings in shares are hoping to see moves more like Facebook than Netflix. Netflix, along with Gilead Sciences and several other stocks famous for their sharp gyrations, were unusually calm following their latest quarterly reports.
Many so-called momentum stocks have rebounded as economic data have been mixed and volatility remained low. Financial Times reports.
LONDON, July 25- Two new leukemia drugs from Johnson& Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib.
The "Fast Money" traders share their final trades of the day.
July 24- Celgene Corp reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.
Some of the names on the move ahead of the open.
July 23- Gilead Sciences Inc said on Wednesday that its new hepatitis C drug Sovaldi had sales of $3.5 billion in the second quarter, demonstrating that the furor over its price has not curtailed early use. Since its December launch, Sovaldi has been prescribed for more than 80,000 patients in the United States and Europe, the company said.
If you have a penchant for quizzes and such, Jim Cramer thinks this question could lead you to a solid stock idea.
Check out which companies are making headlines after the bell Wednesday: Facebook, AT&T, Gilead & more.
July 23- The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer. The FDA approved the use of Zydelig in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia.
Shaking off geopolitical flare-ups for now, analysts say the S&P 500 is taking aim at the 2,000 level, and the next round of earnings news could help.
Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.